(CTRE) CareTrust REIT - Overview
Sector: Real EstateIndustry: REIT - Healthcare Facilities | Exchange NYSE (USA) | Currency USD | Market Cap: 8.360m | Total Return 35.4% in 12m
Stock: Healthcare Properties, Senior Housing, Skilled Nursing
Total Rating 58
Risk 55
Buy Signal -0.84
| Risk 5d forecast | |
|---|---|
| Volatility | 37.5% |
| Relative Tail Risk | 0.89% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.28 |
| Alpha | 30.27 |
| Character TTM | |
|---|---|
| Beta | 0.027 |
| Beta Downside | -0.223 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.19% |
| CAGR/Max DD | 1.32 |
EPS (Earnings per Share)
Revenue
Description: CTRE CareTrust REIT March 05, 2026
CareTrust REIT (CTRE) is a self-administered real estate investment trust (REIT) focused on healthcare properties. REITs are companies that own, operate, or finance income-generating real estate.
The company acquires, develops, and leases skilled nursing, senior housing, and other healthcare-related facilities. These properties are located in the United States and the United Kingdom.
Since its public debut in 2014, CTRE has expanded its portfolio. As of September 30, 2025, it leased 390 healthcare properties to 38 operators across 31 states and the UK, totaling 35,687 operating beds/units. Healthcare REITs often employ triple-net leases, where tenants are responsible for most property expenses.
Additionally, as of the same date, CTRE held 23 other real estate-related investments across 143 healthcare properties with 14,082 operating beds/units, and one financing receivable for 46 properties with 3,820 operating beds/units.
Further research on ValueRay can provide detailed financial metrics and historical performance data for CTRE.
Headlines to watch out for
- Skilled nursing facility occupancy rates impact rental income
- Senior housing demand shifts affect property valuations
- Healthcare regulatory changes influence tenant profitability
- Interest rate fluctuations alter acquisition financing costs
- Tenant operator financial health directly impacts rent collection
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 320.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.49 > 1.0 |
| NWC/Revenue: 26.54% < 20% (prev 112.8%; Δ -86.30% < -1%) |
| CFO/TA 0.08 > 3% & CFO 394.0m > Net Income 320.5m |
| Net Debt (696.2m) to EBITDA (462.1m): 1.51 < 3 |
| Current Ratio: 1.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (204.1m) vs 12m ago 12.13% < -2% |
| Gross Margin: 84.06% > 18% (prev 0.94%; Δ 8.31k% > 0.5%) |
| Asset Turnover: 9.25% > 50% (prev 6.64%; Δ 2.61% > 0%) |
| Interest Coverage Ratio: 8.44 > 6 (EBITDA TTM 462.1m / Interest Expense TTM 43.7m) |
Altman Z'' -0.07
| A: 0.02 (Total Current Assets 300.6m - Total Current Liabilities 195.2m) / Total Assets 5.15b |
| B: -0.10 (Retained Earnings -491.8m / Total Assets 5.15b) |
| C: 0.09 (EBIT TTM 369.0m / Avg Total Assets 4.29b) |
| D: -0.44 (Book Value of Equity -483.7m / Total Liabilities 1.09b) |
| Altman-Z'' Score: -0.07 = B |
Beneish M
| DSRI: 0.61 (Receivables 102.6m/97.2m, Revenue 397.0m/228.3m) |
| GMI: 1.12 (GM 84.06% / 94.06%) |
| AQI: none (AQ_t none / AQ_t-1 none) |
| SGI: 1.74 (Revenue 397.0m / 228.3m) |
| TATA: -0.01 (NI 320.5m - CFO 394.0m) / TA 5.15b) |
| Beneish M-Score: cannot calculate (missing components) |
What is the price of CTRE shares?
As of March 27, 2026, the stock is trading at USD 37.27 with a total of 1,513,667 shares traded.
Over the past week, the price has changed by -5.04%, over one month by -9.41%, over three months by +2.54% and over the past year by +35.42%.
Over the past week, the price has changed by -5.04%, over one month by -9.41%, over three months by +2.54% and over the past year by +35.42%.
Is CTRE a buy, sell or hold?
CareTrust REIT has received a consensus analysts rating of 4.22.
Therefore, it is recommended to buy CTRE.
- StrongBuy: 6
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 1
What are the forecasts/targets for the CTRE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 43.8 | 17.6% |
| Analysts Target Price | 43.8 | 17.6% |
CTRE Fundamental Data Overview March 25, 2026
P/E Trailing = 23.8535
P/E Forward = 12.9702
P/S = 17.549
P/B = 1.9971
P/EG = 1.26
Revenue TTM = 397.0m USD
EBIT TTM = 369.0m USD
EBITDA TTM = 462.1m USD
Long Term Debt = 894.2m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 894.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 696.2m USD (from netDebt column, last quarter)
Enterprise Value = 9.06b USD (8.36b + Debt 894.2m - CCE 198.0m)
Interest Coverage Ratio = 8.44 (Ebit TTM 369.0m / Interest Expense TTM 43.7m)
EV/FCF = 23.89x (Enterprise Value 9.06b / FCF TTM 379.0m)
FCF Yield = 4.19% (FCF TTM 379.0m / Enterprise Value 9.06b)
FCF Margin = 95.48% (FCF TTM 379.0m / Revenue TTM 397.0m)
Net Margin = 80.74% (Net Income TTM 320.5m / Revenue TTM 397.0m)
Gross Margin = 84.06% ((Revenue TTM 397.0m - Cost of Revenue TTM 63.3m) / Revenue TTM)
Gross Margin QoQ = 58.93% (prev none%)
Tobins Q-Ratio = 1.76 (Enterprise Value 9.06b / Total Assets 5.15b)
Interest Expense / Debt = 1.27% (Interest Expense 11.4m / Debt 894.2m)
Taxrate = 1.66% (1.89m / 114.2m)
NOPAT = 362.9m (EBIT 369.0m * (1 - 1.66%))
Current Ratio = 1.54 (Total Current Assets 300.6m / Total Current Liabilities 195.2m)
Debt / Equity = 0.22 (Debt 894.2m / totalStockholderEquity, last quarter 4.04b)
Debt / EBITDA = 1.51 (Net Debt 696.2m / EBITDA 462.1m)
Debt / FCF = 1.84 (Net Debt 696.2m / FCF TTM 379.0m)
Total Stockholder Equity = 3.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.47% (Net Income 320.5m / Total Assets 5.15b)
RoE = 8.99% (Net Income TTM 320.5m / Total Stockholder Equity 3.56b)
RoCE = 8.28% (EBIT 369.0m / Capital Employed (Equity 3.56b + L.T.Debt 894.2m))
RoIC = 8.05% (NOPAT 362.9m / Invested Capital 4.51b)
WACC = 5.61% (E(8.36b)/V(9.25b) * Re(6.08%) + D(894.2m)/V(9.25b) * Rd(1.27%) * (1-Tc(0.02)))
Discount Rate = 6.08% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 38.66%
[DCF] Terminal Value 88.44% ; FCFF base≈321.9m ; Y1≈397.1m ; Y5≈677.5m
[DCF] Fair Price = 84.93 (EV 19.66b - Net Debt 696.2m = Equity 18.96b / Shares 223.2m; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 56.49 | EPS CAGR: 0.0% | SUE: -2.59 | # QB: 0
Revenue Correlation: 88.61 | Revenue CAGR: 33.26% | SUE: 2.36 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.39 | Chg7d=-0.018 | Chg30d=-0.123 | Revisions Net=-1 | Analysts=3
EPS current Year (2026-12-31): EPS=1.59 | Chg7d=-0.066 | Chg30d=-0.198 | Revisions Net=-1 | Growth EPS=+17.0% | Growth Revenue=+13.9%
EPS next Year (2027-12-31): EPS=1.72 | Chg7d=+0.215 | Chg30d=+0.100 | Revisions Net=-1 | Growth EPS=+8.3% | Growth Revenue=+17.9%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.7% (Discount Rate 7.9% - Earnings Yield 4.2%)
[Growth] Growth Spread = +25.7% (Analyst 29.4% - Implied 3.7%)
P/E Forward = 12.9702
P/S = 17.549
P/B = 1.9971
P/EG = 1.26
Revenue TTM = 397.0m USD
EBIT TTM = 369.0m USD
EBITDA TTM = 462.1m USD
Long Term Debt = 894.2m USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 894.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 696.2m USD (from netDebt column, last quarter)
Enterprise Value = 9.06b USD (8.36b + Debt 894.2m - CCE 198.0m)
Interest Coverage Ratio = 8.44 (Ebit TTM 369.0m / Interest Expense TTM 43.7m)
EV/FCF = 23.89x (Enterprise Value 9.06b / FCF TTM 379.0m)
FCF Yield = 4.19% (FCF TTM 379.0m / Enterprise Value 9.06b)
FCF Margin = 95.48% (FCF TTM 379.0m / Revenue TTM 397.0m)
Net Margin = 80.74% (Net Income TTM 320.5m / Revenue TTM 397.0m)
Gross Margin = 84.06% ((Revenue TTM 397.0m - Cost of Revenue TTM 63.3m) / Revenue TTM)
Gross Margin QoQ = 58.93% (prev none%)
Tobins Q-Ratio = 1.76 (Enterprise Value 9.06b / Total Assets 5.15b)
Interest Expense / Debt = 1.27% (Interest Expense 11.4m / Debt 894.2m)
Taxrate = 1.66% (1.89m / 114.2m)
NOPAT = 362.9m (EBIT 369.0m * (1 - 1.66%))
Current Ratio = 1.54 (Total Current Assets 300.6m / Total Current Liabilities 195.2m)
Debt / Equity = 0.22 (Debt 894.2m / totalStockholderEquity, last quarter 4.04b)
Debt / EBITDA = 1.51 (Net Debt 696.2m / EBITDA 462.1m)
Debt / FCF = 1.84 (Net Debt 696.2m / FCF TTM 379.0m)
Total Stockholder Equity = 3.56b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.47% (Net Income 320.5m / Total Assets 5.15b)
RoE = 8.99% (Net Income TTM 320.5m / Total Stockholder Equity 3.56b)
RoCE = 8.28% (EBIT 369.0m / Capital Employed (Equity 3.56b + L.T.Debt 894.2m))
RoIC = 8.05% (NOPAT 362.9m / Invested Capital 4.51b)
WACC = 5.61% (E(8.36b)/V(9.25b) * Re(6.08%) + D(894.2m)/V(9.25b) * Rd(1.27%) * (1-Tc(0.02)))
Discount Rate = 6.08% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares Correlation 3-Years: 100.0 | Cagr: 38.66%
[DCF] Terminal Value 88.44% ; FCFF base≈321.9m ; Y1≈397.1m ; Y5≈677.5m
[DCF] Fair Price = 84.93 (EV 19.66b - Net Debt 696.2m = Equity 18.96b / Shares 223.2m; r=6.0% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 56.49 | EPS CAGR: 0.0% | SUE: -2.59 | # QB: 0
Revenue Correlation: 88.61 | Revenue CAGR: 33.26% | SUE: 2.36 | # QB: 1
EPS next Quarter (2026-06-30): EPS=0.39 | Chg7d=-0.018 | Chg30d=-0.123 | Revisions Net=-1 | Analysts=3
EPS current Year (2026-12-31): EPS=1.59 | Chg7d=-0.066 | Chg30d=-0.198 | Revisions Net=-1 | Growth EPS=+17.0% | Growth Revenue=+13.9%
EPS next Year (2027-12-31): EPS=1.72 | Chg7d=+0.215 | Chg30d=+0.100 | Revisions Net=-1 | Growth EPS=+8.3% | Growth Revenue=+17.9%
[Analyst] Revisions Ratio: -1.00 (0 Up / 1 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.7% (Discount Rate 7.9% - Earnings Yield 4.2%)
[Growth] Growth Spread = +25.7% (Analyst 29.4% - Implied 3.7%)